Must a patent licensee breach its license agreement before challenging the licensed patent? It’s an important question, one that the Supreme Court has just agreed to resolve.
The case, which has been the subject of debate in the patent bar for several years already, is MedImmune Inc. v. Genentech Inc. The legal issue is whether a patent licensee must stop paying royalties before it can initiate a declaratory judgment action challenging the licensed patents.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
